This unregistered trial (n=83) was an open-label, naturalistic observational study of psilocybin-assisted treatment for depression, anxiety, and PTSD in self-referred participants, which found that subjective experiences and demographic factors moderated improvements in mood and personality.
This synthetic trial has been added to our database because a psychedelic paper (about a clinical trial) references this trial, but no (live) registration can be found.
The study investigated the moderating factors of an individual psilocybin-assisted programme, which included intake, preparation, a single 25 mg psilocybin dose (administered via fresh truffle sclerotia), and integration. The cohort consisted of 83 self-referred participants, approximately 45% of whom had a prior or current psychiatric diagnosis. Researchers assessed changes in depression, anxiety, PTSD, and personality structures using standardised scales such as the PHQ-9, GAD-7, and PCL-5.
Results indicated that the treatment led to a reduction in symptoms of anxiety, depression, and PTSD, as well as a decrease in neuroticism over a three-month period. Additionally, increases were observed in personality traits of openness and conscientiousness. The study concluded that mystical-type experiences, emotional breakthroughs, and personal growth served as significant moderators for these positive clinical outcomes.
Individual psilocybin-assisted treatment program consisting of intake, preparation, dosing session, and integration. Dosing involves fresh truffle sclerotia equivalent to 25 mg psilocybin.
Administered via fresh truffle sclerotia; combined with preparatory therapy (1h online, 2h in-person, 1h practical) and integration therapy (2h in-person day after, 1h online 1 week later).